Accuray: Tariffs Are The Latest Obstacle For A Company That Has Struggled To Deliver (Rating Downgrade)
- Accuray has consistently struggled with execution, and now tariffs threaten to significantly impact the company's business in China - it's most promising growth driver. Recent Q3 results showed revenue growth but were overshadowed by weaker guidance and declining orders, particularly impacted by U.S.-China tariffs. The competition in China is intensifying, with local and global players ramping up efforts, challenging Accuray's ability to capitalize on a large market opportunity.
- 05/03/2025
|
ARAY Stock Down Despite Q3 Earnings Beat Estimates, Revenues Up Y/Y
- Accuray reports solid fiscal third-quarter results, witnessing growth in Product & Services revenues and reduced operating expenses.
- 05/01/2025
|
Accuray Incorporated (ARAY) Q3 2025 Earnings Call Transcript
- Accuray Incorporated (NASDAQ:ARAY ) Q3 2025 Earnings Call April 30, 2025 4:30 PM ET Company Participants Jesse Chew - Chief Legal Officer Suzanne Winter - President and Chief Executive Officer Ali Pervaiz - Chief Financial Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Marie Thibault - BTIG Jason Wittes - ROTH Capital Operator Good day and welcome to the Accuray Third Quarter Fiscal 2025 Financial Results Conference Call. [Operator Instructions] Please note this event is being recorded.
- 04/30/2025
|
Accuray (ARAY) Reports Q3 Loss, Tops Revenue Estimates
- Accuray (ARAY) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.06 per share a year ago.
- 04/30/2025
|
Accuray Reports Fiscal 2025 Third Quarter Financial Results
- MADISON, Wis. , April 30, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the third quarter ended March 31, 2025.
- 04/30/2025
|
Here's Why You Should Hold Accuray Stock in Your Portfolio for Now
- ARAY continues to witness strength in its flagship CyberKnife system, along with robust global performance.
- 04/07/2025
|
Accuray CyberKnife® Platform Featured in New Studies Showcasing its Benefits in Central Nervous System Tumors Presented at Radiosurgery Society Scientific Meeting
- Data Also Highlights Continued Clinical Advances Using the CyberKnife System That are Making High Quality Care an Option for People Who Previously Had Limited Choices MADISON, Wis. , April 3, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new data on the clinical use of the CyberKnife ® System reinforce the device's broad-based radiation treatment capabilities for central nervous system (CNS) tumors.
- 04/03/2025
|
Accuray to Participate at 37th Annual Roth Conference
- MADISON, Wis. , March 12, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today announced its participation in the 37th Annual Roth Conference taking place on March 16 -18, 2025 in Dana Point, California.
- 03/12/2025
|
Here's Why You Should Hold Accuray Stock in Your Portfolio for Now
- ARAY continues to witness strength in its flagship CyberKnife system, along with robust global performance.
- 03/05/2025
|
ARAY Stock Up as Q2 Earnings & Revenues Beat Estimates, Margins Up
- Accuray delivers solid fiscal second-quarter results, witnessing growth in Product revenues and reduced operating expenses.
- 02/06/2025
|
Accuray Incorporated (ARAY) Q2 2025 Earnings Call Transcript
- Accuray Incorporated (NASDAQ:ARAY ) Q2 2025 Results Conference Call February 5, 2025 4:30 PM ET Company Participants Jesse Chew - Chief Legal Officer Suzanne Winter - President and Chief Executive Officer Ali Pervaiz - Chief Financial Officer Conference Call Participants Marie Thibault - BTIG Brooks O'Neil - Lake Street Capital Markets Operator Good day, and welcome to the Accuray Fiscal 2025 Second Quarter Financial Results Conference Call. All participants will be in a listen-only mode.
- 02/05/2025
|
Accuray (ARAY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
- Although the revenue and EPS for Accuray (ARAY) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 02/05/2025
|
Accuray (ARAY) Q2 Earnings and Revenues Top Estimates
- Accuray (ARAY) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to loss of $0.10 per share a year ago.
- 02/05/2025
|
Accuray Reports Strong Fiscal 2025 Second Quarter Financial Results & Raises Guidance
- MADISON, Wis., Feb. 5, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the second quarter ended December 31, 2024.
- 02/05/2025
|
Accuray Announces First 100 Patient Treatment Regimens Completed in China Using the Tomo® C Radiation Treatment Delivery System, a CNNC-Accuray Joint Venture Product
- MADISON, Wis. , Jan. 23, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Shandong Cancer Hospital and Institute has achieved a milestone with the completion of treatment for 100 patients using the Tomo® C Radiation Treatment Delivery System, a product built in China through the CNNC-Accuray joint venture.
- 01/23/2025
|
Accuray to Report Second Quarter Fiscal 2025 Financial Results on February 5, 2025
- MADISON, Wis. , Jan. 22, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the second quarter of fiscal year 2025, ended December 31, 2024, during a conference call hosted by company management at 1:30 p.m.
- 01/22/2025
|
Leonel Peralta to Join Accuray as Chief Operations Officer
- MADISON, Wis. , Jan. 21, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Leonel Peralta is joining the company as Senior Vice President, Chief Operations Officer, effective February 3, 2025.
- 01/21/2025
|
Accuray (ARAY) Shows Fast-paced Momentum But Is Still a Bargain Stock
- Accuray (ARAY) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
- 01/20/2025
|
ARAY Stock Gains as China Approves Latest Radiation Therapy Solutions
- Accuray announces the approval of the Chinese NMPA for its latest radiation therapy solutions.
- 01/14/2025
|
Accuray Announces China National Medical Products Administration Approval of the Radixact® SynC™ and CyberKnife® S7™ Systems; Expands on the China Product Portfolio that Includes the Recently Approved Tomo® C System
- MADISON, Wis. , Jan. 13, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company's Radixact SynC™ System and CyberKnife® S7™ System have been approved by the Chinese National Medical Products Administration (NMPA).
- 01/13/2025
|
Here's Why You Should Add Accuray Stock to Your Portfolio Now
- ARAY's solid product demand and revenue growth raise optimism about the stock.
- 01/08/2025
|
Accuray - There's Value If Linac Sales Accelerate, But That's A Big 'If'
- Impressive revenue growth remains elusive for Accuray despite the potential in China, and there are ongoing challenges with profitability, competition, and market scale. The last quarter's results showed mixed performance, with better than expected revenue and a small guidance boost, but overall product sales were down and the backlog shrank modestly. Sustainability remains a key issue; China is growing nicely, but revenue in Japan weakened and the company has seen its installed base in the U.S. shrink, pressuring service revenue.
- 01/07/2025
|
Here Is Why Bargain Hunters Would Love Fast-paced Mover Accuray (ARAY)
- If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Accuray (ARAY) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
- 01/03/2025
|
5 Beaten-Down MedTech Stocks Set to Rebound in 2025
- Investors may want to take a closer look at discounted stocks, such as MCK, HAE, ARAY, LIVN and PBH, in the present market landscape.
- 12/30/2024
|
ARAY Stock Falls Despite Positive Data of CyberKnife in Treating BSM
- Accuray announces positive study data for its CyberKnife System in treating brainstem metastases.
- 12/19/2024
|
New Data Indicates the CyberKnife® System Can Provide a Safe and Effective Treatment Option to Control Brainstem Metastases, an Extremely Challenging Location to Treat
- Study Builds on Extensive Published Literature Highlighting the Benefits of the CyberKnife System in the Treatment of a Wide Range of Neurological Indications MADISON, Wis., Dec. 18, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today an international retrospective multicenter analysis found that radiosurgery (SRS) and fractionated stereotactic radiotherapy (FSRT), delivered with the CyberKnife® System, can provide an effective and time-saving treatment option for brainstem metastases (BSM).
- 12/18/2024
|
Looking for a Fast-paced Momentum Stock at a Bargain? Consider Accuray (ARAY)
- If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Accuray (ARAY) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
- 12/16/2024
|
Here's Why You Should Add Accuray Stock in Your Portfolio Now
- ARAY's solid product demand and revenue growth raise optimism about the stock.
- 12/10/2024
|
Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules
- MADISON, Wis. , Nov. 26, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported, as required by NASDAQ Listing Rules, equity inducement awards to Mike Murphy, the company's new Vice President, Corporate Controller.
- 11/26/2024
|
Accuray Q1 Earnings Meet Estimates, Sales Beat, Gross Margin Shrinks
- ARAY's first-quarter fiscal 2025 earnings meet estimates. Both the top and bottom lines deteriorate year over year.
- 11/07/2024
|
Accuray Incorporated (ARAY) Q1 2025 Earnings Call Transcript
- Accuray Incorporated (ARAY) Q1 2025 Earnings Call Transcript
- 11/06/2024
|
Accuray (ARAY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
- The headline numbers for Accuray (ARAY) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 11/06/2024
|
Accuray (ARAY) Reports Q1 Loss, Tops Revenue Estimates
- Accuray (ARAY) came out with a quarterly loss of $0.04 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.03 per share a year ago.
- 11/06/2024
|
Accuray Reports Fiscal 2025 First Quarter Financial Results
- Strong Start to Fiscal Year, Raises 2025 Guidance MADISON, Wis. , Nov. 6, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the first quarter ended September 30, 2024.
- 11/06/2024
|
Accuray to Report First Quarter Fiscal 2025 Financial Results on November 6, 2024
- MADISON, Wis., Oct. 23, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the first quarter of fiscal year 2025, ended September 30, 2024, during a conference call hosted by company management at 1:30 p.m.
- 10/23/2024
|
Accuray Appoints Michael Murphy as VP, Corporate Controller
- MADISON, Wis. , Oct. 21, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Michael Murphy, CPA has joined the company as Vice President, Corporate Controller.
- 10/21/2024
|
Here's Why You Should Retain Accuray Stock in Your Portfolio Now
- ARAY's solid product demand and revenue growth raise optimism about the stock.
- 10/17/2024
|
Accuray President and Chief Executive Officer Suzanne Winter Returns from Medical Leave of Absence
- MADISON, Wis. , Oct. 15, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced that, effective as of today, Suzanne Winter has returned from her temporary medical leave and assumed her full duties as President and Chief Executive Officer.
- 10/15/2024
|
Accuray Celebrates Opening of Genolier Innovation Hub in Switzerland, Initiation of CyberKnife® S7™ System Medical Professional Training
- Accuray is the first industry partner to open a facility at the Genolier Innovation Hub, created to provide opportunities for clinician-industry collaborations that can help accelerate improvements in patient care New Accuray CyberComm™ tool was used to significantly reduce the CyberKnife® S7™ System's commissioning time and enable product training in Genolier to begin more quickly MADISON, Wis. , Sept. 30, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the initiation of CyberKnife® S7™ System medical professional training at its education center located within the newly opened Genolier Innovation Hub, a fully-owned subsidiary of AEVIS VICTORIA SA, in Switzerland.
- 09/30/2024
|
Here's Why You Should Retain Accuray Stock in Your Portfolio Now
- ARAY's solid product demand and revenue growth raise optimism about the stock.
- 09/17/2024
|
ARAY Stock Up Following the Use of SGRT on Cancer Patients in Japan
- The latest adoption of Accuray's Radixact System and VitalHold package is likely to improve the care provided to cancer patients and their experience.
- 09/16/2024
|
Gifu Prefectural General Medical Center Achieves Milestone with Treatment of the First Cancer Patients in Japan Using the Accuray Radixact® System and VitalHold™ Solution
- The Technology Will Play an Important Role in the Hospital's Plan to Expand Patient Access to High Precision Radiation Therapy Treatments MADISON, Wis. , Sept. 10, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Gifu Prefectural General Medical Center is setting a new standard in cancer care in Japan as the first hospital in the country to treat patients with surface-guided radiation therapy (SGRT) using the company's Radixact ® Radiation Delivery System and VitalHold™* package.
- 09/10/2024
|
Accuray President and Chief Executive Officer Suzanne Winter to Take Temporary Medical Leave of Absence
- MADISON, Wis. , Sept. 3, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that President and Chief Executive Officer Suzanne Winter will be taking a temporary medical leave of absence to receive care for a treatable form of cancer, effective immediately.
- 09/03/2024
|
Accuray Stock Rises After Helix System Wins CE Mark for Cancer Care
- ARAY's Helix system, now CE Mark approved, aims to close global cancer care gaps with cost-effective, high-throughput radiotherapy for underserved regions.
- 08/28/2024
|
Accuray Receives CE Mark for a New Helical Radiation Delivery System, Accuray Helix™
- Developed for India and other countries where patient access to care with radiotherapy is challenged and where versatility and ease of use are a high priority Drives the next phase of company's strategic plan to expand its portfolio of helical radiation therapy delivery systems MADISON, Wis. , Aug. 27, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the company has received CE Mark for Accuray Helix™, a CT-guided helical radiotherapy system designed to provide high-performance and high-throughput.
- 08/27/2024
|
Accuray Remains A Perpetual 'Next Year Is Our Year' Story
- Accuray posts a strong end to the fiscal year with 16% revenue growth in FQ4, beating expectations and restoring some confidence for the upcoming year. Management's claim that weaker U.S. sales are a consequence of a weaker capex environment don't fully align with the reported U.S. sales results of other med-tech capital equipment companies. Global opportunities remain promising, especially in China's value-priced linac market, and opportunities in Japan, India, other emerging markets are meaningful.
- 08/18/2024
|
Accuray's (ARAY) Radixact for Cancer Treatment Debuts in US
- Accuray's (ARAY) Radixact System with VitalHold technology is set to enhance precision and comfort in radiation therapy.
- 08/15/2024
|
Accuray (ARAY) Q4 Earnings Lag Estimates, Gross Margin Shrinks
- Despite improving product sales, Accuray (ARAY) reports mixed fourth-quarter fiscal 2024 results.
- 08/15/2024
|
Accuray Incorporated (ARAY) Q4 2024 Earnings Call Transcript
- Accuray Incorporated (NASDAQ:ARAY ) Q4 2024 Earnings Call Transcript August 14, 2024 4:30 PM ET Company Participants Jesse Chew - SVP and Chief Legal Officer Suzanne Winter - President and CEO Ali Pervaiz - CFO Conference Call Participants Young Li - Jefferies Marie Thibault - BTIG Brooks O'Neil - Lake Street Capital Markets Jason Wittes - Roth Capital Operator Good day, and welcome to the Accuray Fscal 2024 Fourth Quarter Financial Results Call. All participants will be in listen-only mode.
- 08/14/2024
|
Accuray Reports Fourth Quarter and Fiscal 2024 Financial Results
- 14% Revenue and 8% Orders Growth in Q4; Company issues FY25 Guidance MADISON, Wis. , Aug. 14, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal 2024, ended June 30, 2024.
- 08/14/2024
|
Halifax Health in Florida is First in the U.S. to Treat Patients with Cancer Using the Accuray Radixact® Radiation Delivery System and VitalHold™ Technology
- New Technology Provides Advanced Patient Positioning Capabilities With the Radixact System, Making it Easier to Deliver Fast and Effective Radiotherapy Treatments MADISON, Wis. and DAYTONA BEACH, Fla.
- 08/13/2024
|
Here's Why You Should Retain Accuray (ARAY) Stock for Now
- Accuray's (ARAY) solid product demand raises optimism about the stock.
- 08/12/2024
|
Accuray to Report Fourth Quarter Fiscal 2024 Financial Results on August 14, 2024
- MADISON, Wis. , July 31, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the fourth quarter of fiscal year 2024, ended June 30, 2024, during a conference call hosted by company management at 1:30 p.m.
- 07/31/2024
|
3 Penny Stock Lotto Tickets With 100X Potential
- When it comes to investing in top penny stocks, a word of caution. Always do your due diligence before buying.
- 07/10/2024
|
Heidelberg University Hospital in Germany Invests in Fourth Accuray Radiotherapy Device, the Radixact® System, to Improve Cancer Patient Care
- The Radixact System will be supplied with ClearRT®, Synchrony®, and the VOLO™ Ultra Optimizer to enhance radiation treatment delivery precision and speed Heidelberg University Hospital is recognized worldwide for excellence in patient care and practice changing research MADISON, Wis. , June 27, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that long-term customer Heidelberg University Hospital in Heidelberg, Germany, has selected the company's Radixact ® System, equipped with its proprietary ClearRT ®, Synchrony ® and VOLO™ Ultra Optimizer solutions, to help transform their approach to cancer care.
- 06/27/2024
|
Accuray (ARAY), TrueNorth Unite to Aid Radiation Departments
- Accuray (ARAY) announces an agreement with TrueNorth to provide radiation oncology departments with third-party support designed to improve their department's capabilities.
- 06/24/2024
|
Accuray and TrueNorth Medical Physics Sign Agreement to Provide Radiation Oncology Support Intended to Advance Cancer Care for More Patients
- MADISON, Wis. , June 20, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today an agreement with TrueNorth Medical Physics LLC to provide radiation oncology departments with third-party support designed to enhance their department's capabilities.
- 06/20/2024
|
3 Millionaire-Maker Penny Stocks Set to Surge by 1,000%: June Edition
- By now, you know the dangers of “millionaire-maker penny stocks.” Whenever we even mention a penny stock, we add a disclaimer at the end of articles.
- 06/14/2024
|
Accuray's (ARAY) Precision TPS Gets Approved by China's NMPA
- Accuray (ARAY) announces the approval of the Accuray Precision Treatment Planning System by the Chinese Medical Products Administration.
- 06/13/2024
|
Accuray Announces Approval of the Accuray Precision® Treatment Planning System by China's National Medical Products Administration
- MADISON, Wis. , June 12, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the registration dossier for the Accuray Precision ® Treatment Planning System (TPS) has been approved by the Chinese National Medical Products Administration (NMPA).
- 06/12/2024
|
Accuray (ARAY) Up 2% Since Last Earnings Report: Can It Continue?
- Accuray (ARAY) reported earnings 30 days ago. What's next for the stock?
- 05/31/2024
|
New Strong Sell Stocks for May 31st
- ASGN, ARAY and BGS have been added to the Zacks Rank #5 (Strong Sell) List on May 31, 2023.
- 05/31/2024
|
New Strong Sell Stocks for May 24th
- DDD, ARAY and BNTGY have been added to the Zacks Rank #5 (Strong Sell) List on May 24, 2023.
- 05/24/2024
|
Accuray to Participate in the Jefferies Global Healthcare Conference 2024
- MADISON, Wis. , May 22, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the Jefferies Global Healthcare Conference 2024.
- 05/22/2024
|
Accuray (ARAY) Q3 Earnings Lag Estimates, Gross Margin Contracts
- Despite strength in radiation oncology, Accuray (ARAY) reports dismal third-quarter fiscal 2024 results.
- 05/02/2024
|
Accuray Incorporated (ARAY) Q3 2024 Earnings Call Transcript
- Accuray Incorporated (NASDAQ:ARAY ) Q3 2024 Earnings Conference Call May 1, 2024 4:30 PM ET Company Participants Jesse Chew - SVP and Chief Legal Officer Suzanne Winter - President and CEO Ali Pervaiz - CFO Conference Call Participants Young Li - Jefferies Brooks O'Neil - Lake Street Jason Wittes - ROTH MKM Operator Good afternoon, and welcome to the Accuray conference call to review financial results for the third quarter of fiscal year 2024 which ended March 31 of 2024. All participants will be in listen-only mode.
- 05/01/2024
|
Accuray (ARAY) Reports Q3 Loss, Lags Revenue Estimates
- Accuray (ARAY) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.01 per share a year ago.
- 05/01/2024
|
Accuray Reports Fiscal 2024 Third Quarter Financial Results
- MADISON, Wis. , May 1, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the third quarter and nine-months ended March 31, 2024.
- 05/01/2024
|
Accuray Showcases Advances in Radiation Therapy Solutions Designed to Improve the Cancer Treatment Experience at ESTRO 2024
- Celebrates 30 Years of Innovation Through Collaboration and the Development of Technologies That Have Helped Set the Standard of Care for the Industry MADISON, Wis. , April 25, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company is showcasing advances in hardware and software designed to improve the cancer treatment experience, at ESTRO 2024.
- 04/25/2024
|
Accuray Expands Global Training Center Network With Opening of New Facility in Genolier, Switzerland
- The new center is the most recent addition to the company's existing training hubs in Madison, Wisconsin (U.S.), Tokyo, Japan and Tianjin, China Each facility offers a range of educational opportunities designed to advance patient care using the Accuray CyberKnife® and Radixact® Systems MADISON, Wis., April 18, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that as part of its commitment to advancing patient care the company has opened a new training center in Genolier, Switzerland, that will serve as the European education hub for radiosurgery and radiotherapy product training, and sharing of best practices and innovative techniques using the latest model Accuray CyberKnife ® and Radixact ® Radiation Treatment Delivery Systems and Accuray Precision ® Treatment Planning System.
- 04/18/2024
|
Accuray to Report Third Quarter Fiscal 2024 Financial Results on May 1, 2024
- MADISON, Wis. , April 17, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the third quarter of fiscal year 2024, ended March 31, 2024, during a conference call hosted by company management at 1:30 p.m.
- 04/17/2024
|
Accuray Getting Very Little Love Ahead Of A Coming Revenue Ramp
- Despite management guidance that points to significant revenue acceleration in the next two quarters, Accuray shares have languished. Market skepticism can be tied in part to the company's track record - despite multiple efforts to improve its portfolio and go-to-market strategy, market share growth has been very modest. The company's entry into China's Type B market could be its last best chance to change the narrative - meaningful share in a $600M/year market should be transformative.
- 04/07/2024
|
Accuray's (ARAY) CyberKnife Improves Prostate Cancer Treatment
- Accuray (ARAY) announces the latest data that supports the use of its CyberKnife System in the treatment of recurrent prostate cancer with stereotactic body radiation therapy.
- 03/27/2024
|
New Data from Two Clinical Studies Indicate High-Risk and Recurrent Prostate Cancers Can be Effectively Treated in 5 Days Using the Accuray CyberKnife® System
- Data Also Underscores Potential Benefits of CyberKnife System Sub-millimeter Accuracy in Preserving Quality of Life after Treatment for Prostate Cancer MADISON, Wis. , March 26, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new data presented at the 2024 Radiosurgery Society Meeting in Chicago, Illinois support the use of the CyberKnife ® System in the treatment of high-risk and recurrent prostate cancer.
- 03/26/2024
|
Here's Why You Should Retain Accuray (ARAY) Stock for Now
- Accuray's (ARAY) solid product demand raises optimism about the stock.
- 03/20/2024
|
Accuray Incorporated to Speak at 36th Annual Roth Conference
- Company to Take Part in Fireside Chat Monday, March 18, 2024 at 12:30pm PST / 3:30pm EST MADISON, Wis. , March 4, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the 36th Annual Roth Conference.
- 03/04/2024
|
Accuray (ARAY) Up 1.6% Since Last Earnings Report: Can It Continue?
- Accuray (ARAY) reported earnings 30 days ago. What's next for the stock?
- 03/01/2024
|
Accuray Incorporated to Speak at Oppenheimer 34th Annual Healthcare MedTech & Services Conference
- Company to Take Part in Fireside Chat Tuesday, March 12, 2024 at 7:00am PST / 10:00am EST MADISON, Wis. , Feb. 27, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference taking place March 12-13, 2024.
- 02/27/2024
|
7 Screaming Stock Buys for Under $5
- While most financial advisors will probably steer you away from under $5 stocks, they have their benefits. Just like in football – the American kind – you can't just run up the gut.
- 02/21/2024
|
Three Reasons to Retain Accuray (ARAY) Stock in Your Portfolio
- The continued solid demand for Accuray's (ARAY) products raises optimism about the stock.
- 02/20/2024
|
Quebec Cancer Center is First in Canada to Treat Cancer Patients Using the Accuray Radixact® System
- Montérégie Integrated Cancer Center, part of Charles-LeMoyne Hospital, is a center of excellence and recognized leader in the treatment of cancer in the province of Quebec The Radixact System is equipped with ClearRT™ and Synchrony®, advanced technologies designed to improve treatment outcomes for more patients each day MADISON, Wis. , Feb. 13, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the team at Quebec's Montérégie Integrated Cancer Center, part of Charles-LeMoyne Hospital, is the first in Canada to treat cancer patients using the company's Radixact ® radiation therapy delivery system.
- 02/13/2024
|
Accuray to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
- MADISON, Wis. , Feb. 5, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place on February 13, 2024.
- 02/05/2024
|
Accuray (ARAY) Q2 Earnings Lag Estimates, Gross Margin Contracts
- Despite robust Services revenues, Accuray (ARAY) reports dismal second-quarter fiscal 2024 results.
- 02/01/2024
|
Accuray Incorporated (ARAY) Q2 2024 Earnings Call Transcript
- Accuray Incorporated (ARAY) Q2 2024 Earnings Call Transcript
- 01/31/2024
|
Accuray (ARAY) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
- The headline numbers for Accuray (ARAY) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 01/31/2024
|
Unveiling Accuray (ARAY) Q2 Outlook: Wall Street Estimates for Key Metrics
- Besides Wall Street's top -and-bottom-line estimates for Accuray (ARAY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.
- 01/30/2024
|
Accuray's (ARAY) CyberKnife S7 to Enhance Radiation Treatment
- Accuray's (ARAY) latest generation CyberKnife S7 System is expected to boost the cancer treatment capabilities of the Providence Swedish Radiosurgery Center.
- 01/29/2024
|
Accuray to Report Second Quarter Fiscal 2024 Financial Results on January 31, 2024
- MADISON, Wis. , Jan. 16, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the second quarter of fiscal year 2024, ended December 31, 2023, during a conference call hosted by company management at 1:30 p.m.
- 01/16/2024
|
Here's Why You Should Retain Accuray (ARAY) Stock for Now
- The continued solid demand for Accuray's (ARAY) products raises optimism about the stock.
- 01/08/2024
|
Accuray (ARAY) Launches VitalHold in Japan for Use With Radixact
- Accuray's (ARAY) VitalHold is likely to transform breast cancer treatment in Japan by integrating SGRT for precise radiotherapy. It may become a game-changer for patients and medical staff.
- 12/06/2023
|
Accuray (ARAY) Q1 Earnings In-Line With Estimates, Revenues Top
- Accuray (ARAY) reports a solid fiscal first quarter top line on the back of robust Product revenues.
- 11/08/2023
|
Accuray Incorporated (ARAY) Q1 2024 Earnings Call Transcript
- Accuray Incorporated (NASDAQ:ARAY ) Q1 2024 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Jesse Chew - SVP and Chief Legal Officer Suzanne Winter - President and CEO Ali Pervaiz - CFO Conference Call Participants Young Li - Jefferies Brooks O'Neil - Lake Street Capital Markets Brandon Carney - B. Riley Operator Good afternoon and welcome to the Accuray's First Quarter 2024 Conference Call.
- 11/07/2023
|
Compared to Estimates, Accuray (ARAY) Q1 Earnings: A Look at Key Metrics
- The headline numbers for Accuray (ARAY) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 11/07/2023
|
With Chinese Type B Approval In Hand, 'Now Or Never' Approaches For Accuray
- Accuray's China JV recently received approval to sell its locally-produced Tomo C rad-onc system for China's Type B market - an opportunity that management estimates at $3B over 5 years. Management has a good track record in China, but there's a long history here of not delivering on potential growth opportunities and both Varian and Elekta are targeting China. China isn't the only driver, as Japan and segments of the U.S. market (including SBRT) could perform better, but execution is paramount.
- 10/06/2023
|
Accuray's (ARAY) Tomo C Radiation System Gets Approval in China
- Accuray's (ARAY) Tomo C radiation therapy system will enable medical care teams to provide personalized and highly precise treatments.
- 10/05/2023
|
Accuray's (ARAY) New Offering to Boost Radiation Treatment Plans
- Accuray's (ARAY) latest offering is likely to improve radiation treatment.
- 10/03/2023
|
Why Is Accuray (ARAY) Down 15.2% Since Last Earnings Report?
- Accuray (ARAY) reported earnings 30 days ago. What's next for the stock?
- 09/08/2023
|
Accuray Incorporated - Impressive Growth As Orders Expands
- Accuray Incorporated has shown impressive growth in its share price and revenues, making it an attractive investment opportunity in the healthcare equipment market. The company is becoming a leader in the precision radiation therapy market and has a positive market outlook. ARAY's innovative radiosurgery and radiation therapy systems play a crucial role in cancer treatment and have a large market to tap into, particularly in China and Brazil.
- 08/19/2023
|
Accuray's (ARAY) Treatment Options to be Boosted Post FDA's Nod
- Accuray's (ARAY) latest regulatory approval is likely to improve breast cancer treatment.
- 08/15/2023
|
New Strong Sell Stocks for August 11th
- NGLOY, ARAY and BANR have been added to the Zacks Rank #5 (Strong Sell) List on August 11, 2023.
- 08/11/2023
|
Accuray (ARAY) Q4 Earnings and Revenues Lag Estimates
- Accuray (ARAY) reports a solid fiscal fourth quarter top line on the back of robust segmental performances.
- 08/10/2023
|
Accuray (ARAY) Reports Q4 Earnings: What Key Metrics Have to Say
- Although the revenue and EPS for Accuray (ARAY) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 08/09/2023
|
Accuray (ARAY) Hits 52-Week High: What's Aiding the Stock?
- Investors are optimistic about Accuray's (ARAY) solid product portfolio.
- 05/24/2023
|
Accuray (ARAY) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
- Although the revenue and EPS for Accuray (ARAY) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 04/26/2023
|
Accuray (ARAY) Q3 Earnings and Revenues Beat Estimates
- Accuray (ARAY) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to loss of $0.01 per share a year ago.
- 04/26/2023
|
Here's Why You Should Retain Accuray (ARAY) Stock for Now
- Investors continue to be optimistic about Accuray (ARAY) owing to strong demand for its products.
- 03/20/2023
|
3 Cutting-Edge Healthcare Stocks That Can Pay Off Big Time
- Healthcare costs in America and the world are set to rise in the foreseeable future. All thanks to an aging population, and the expectation that healthcare companies will be able to cure more of our diseases.
- 03/18/2023
|
Accuray (ARAY) Q2 Earnings and Revenues Top Estimates
- Despite solid product demand, Accuray (ARAY) reports an overall soft fiscal Q2 performance.
- 02/02/2023
|
Why Shares of Accuray Jumped Thursday
- The radiation-oncology machine company saw shares rise after it released an earnings report.
- 02/02/2023
|
Accuray Achieves Record Product Revenue, But There's Much Work Still To Be Done
- Accuray's revenue did fall year-over-year as reported, but the company beat expectations and product revenue reached a new all-time high with 8% year-over-year constant-currency growth. Orders grew sequentially at a double-digit rate and net orders doubled; Accuray still has work to do to reach $100M in gross quarterly orders.
- 02/02/2023
|
Accuray Incorporated (ARAY) Q2 2023 Earnings Call Transcript
- Accuray Incorporated (NASDAQ:ARAY ) Q2 2023 Earnings Conference Call February 1, 2023 4:30 PM ET Company Participants Jesse Chew - Senior Vice President, General Counsel & Corporate Secretary Suzanne Winter - Chief Executive Officer Ali Pervaiz - Chief Financial Officer Conference Call Participants Marie Thibault - BTIG Josh Jennings - Cowen Neil Chatterji - B. Riley Brooks O'Neil - Lake Street Capital Markets Jason Wittes - Loop Capital Operator Good day and welcome to the Accuray Second Quarter Fiscal 2023 Financial Results.
- 02/01/2023
|
Accuray (ARAY) Reports Q2 Loss, Tops Revenue Estimates
- Accuray (ARAY) delivered earnings and revenue surprises of 33.33% and 7.98%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 02/01/2023
|
Accuray's (ARAY) Q1 Earnings and Revenues Lag Estimates
- Despite solid product demand, Accuray (ARAY) reports an overall soft Q1 performance.
- 11/03/2022
|
Accuray Incorporated (ARAY) Q1 2023 Earnings Call Transcript
- Accuray Incorporated (NASDAQ:ARAY ) Q1 2023 Results Conference Call November 2, 2022 4:30 AM ET Company Participants Ken Mobeck - Vice President of Finance and Investor Relations Suzanne Winter - Chief Executive Officer Ali Pervaiz - Chief Financial Officer Conference Call Participants Charlie Montang - Lake Street Capital Josh Jennings - Cowen Neil Chatterji - B. Riley Sam Eiber - BTIG Jason Wittes - Loop Capital Operator Good afternoon, and welcome to the Accuray First Quarter 2023 Financial Results Conference Call.
- 11/02/2022
|
Accuray (ARAY) Reports Q1 Loss, Misses Revenue Estimates
- Accuray (ARAY) delivered earnings and revenue surprises of -500% and 8.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/02/2022
|
3 Reasons to Hold Accuray (ARAY) Stock in Your Portfolio
- Investors continue to be optimistic about Accuray (ARAY) owing to strong demand for its products.
- 09/28/2022
|
Accuray's (ARAY) Latest Collaboration to Improve Patient Care
- Accuray (ARAY) partners with Genolier Innovation Hub to unite companies from the MedTech, pharma and biosciences sectors with physicians and scientists for better patient outcomes.
- 09/08/2022
|
Accuray (ARAY) Q4 Earnings Beat Estimates, Margins Down
- Despite solid Product revenues, Accuray (ARAY) reports an overall soft Q4 performance.
- 08/11/2022
|
Accuray Incorporated (ARAY) CEO Suzanne Winter on Q4 2022 Results - Earnings Call Transcript
- Accuray Incorporated (NASDAQ:ARAY ) Q4 2022 Results Conference Call August 10, 2022 4:30 PM ET Company Participants Ken Mobeck - Vice President-Finance Suzanne Winter - President & Chief Executive Officer Ali Pervaiz - Chief Financial Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Neil Chatterji - B. Riley Marie Thibault - BTIG Josh Jennings - Cowen Jason Wittes - Loop Capital Operator Good afternoon, and welcome to the Accuray Fourth Quarter 2022 Financial Results Conference Call.
- 08/10/2022
|
Accuray (ARAY) Reports Q4 Loss, Tops Revenue Estimates
- Accuray (ARAY) delivered earnings and revenue surprises of 33.33% and 4.93%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/10/2022
|
3 Reasons to Add Accuray (ARAY) Stock to Your Portfolio Now
- Investors continue to be optimistic about Accuray (ARAY) owing to strong demand for its products.
- 07/13/2022
|
Here's Why You Should Hold on to Accuray (ARAY) Stock For Now
- Investors continue to be optimistic about Accuray (ARAY) owing to its solid global reach.
- 06/13/2022
|
Accuray's (ARAY) New Tie-Up to Augment Treatment Planning
- Accuray (ARAY) partners with Limbus AI to enhance the treatment planning process and patient care.
- 06/03/2022
|
Down 20% in 4 Weeks, Here's Why Accuray (ARAY) Looks Ripe for a Turnaround
- Accuray (ARAY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- 05/05/2022
|
Accuray (ARAY) Q3 Earnings Beat Estimates, Revenues Lag
- Despite strong product demand, Accuray (ARAY) reports an overall soft Q3 performance.
- 04/29/2022
|
Accuray's (ARAY) CEO Josh Levine on Q3 2022 Results - Earnings Call Transcript
- Accuray Incorporated (NASDAQ:ARAY ) Q3 2022 Earnings Conference Call April 27, 2022 4:30 PM ET Company Participants Ken Mobeck – Vice President-Finance Josh Levine – Chief Executive Officer Suzanne Winter – President Brandy Green – Interim Chief Financial Officer Conference Call Participants Brooks O'Neil – Lake Street Capital Markets Marie Thibault – BTIG Josh Jennings – Cowen Frank Pinal – Jefferies Jason Wittes – Loop Capital Operator Good afternoon, and welcome to the Accuray Third Quarter Fiscal 2022 Financial Results Conference Call. [Operator instructions] Please note this event is being recorded.
- 04/27/2022
|
Accuray to Report Third Quarter Fiscal 2022 Financial Results on April 27, 2022
- SUNNYVALE, Calif. , April 13, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the third quarter of fiscal year 2022, ended March 31, 2022, after the market close on April 27, 2022.
- 04/13/2022
|
Accuray's (ARAY) CyberKnife Effective for Relief From TN Pain
- Latest data indicates that Accuray's (ARAY) CyberKnife System is effective in providing long-lasting pain relief to patients suffering from TN.
- 04/04/2022
|
3 Reasons to Retain Accuray (ARAY) Stock in Your Portfolio
- Investors continue to be optimistic about Accuray (ARAY) owing to its solid global reach.
- 04/01/2022
|
New Strong Sell Stocks for March 21st
- ARAY, AKU, and ANIK have been added to the Zacks Rank #5 (Strong Sell) List on March 21, 2022
- 03/21/2022
|
Accuray's (ARAY) CyberKnife S7 System Gets Chosen by CARTI
- Accuray's (ARAY) CyberKnife S7 System gets selected by the CARTI medical care team, thereby offering better cancer care in Arkansas via expanded access to advanced technology.
- 03/09/2022
|
3 Penny Stocks To Buy Now According To Reddit Traders
- Reddit penny stocks for your February 2022 watch list. The post 3 Penny Stocks To Buy Now According To Reddit Traders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 02/11/2022
|
New Strong Sell Stocks for January 27th
- ARAY, XAIR, and EMKR have been added to the Zacks Rank #5 (Strong Sell) List on January 27, 2022
- 01/27/2022
|
Accuray Incorporated (ARAY) CEO Joshua Levine on Q2 2022 Earnings Call Transcript
- Accuray Incorporated (ARAY) CEO Joshua Levine on Q2 2022 Earnings Call Transcript
- 01/26/2022
|
Accuray (ARAY) Reports Break-Even Earnings for Q2
- Accuray (ARAY) delivered earnings and revenue surprises of -100% and 10.84%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 01/26/2022
|
Accuray to Report Second Quarter Fiscal 2022 Financial Results on January 26, 2022
- SUNNYVALE, Calif., Jan. 12, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the second quarter of fiscal year 2022, ended December 31, 2021, after the market close on Wednesday, January 26, 2022.
- 01/12/2022
|
3 Reasons to Add Accuray (ARAY) Stock to Your Portfolio
- Investors continue to be optimistic about Accuray (ARAY) owing to its slew of software upgrades.
- 01/03/2022
|
5 Buy-Rated Stocks Trading Under $10 With Huge 2022 New Year's Potential
- While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
- 01/01/2022
|
Is Accuray (ARAY) Outperforming Other Medical Stocks This Year?
- Here is how Accuray (ARAY) and Assertio (ASRT) have performed compared to their sector so far this year.
- 12/23/2021
|
Accuray's (ARAY) CyberKnife System Gets Shonin Approval
- Accuray's (ARAY) CyberKnife System can now be marketed in Japan post the Shonin approval.
- 12/20/2021
|
3 Top Medical Instruments Stocks to Counter Industry Headwinds
- The Zacks Medical - Instruments industry is growing on COVID-support business gains. TMO, STE and ARAY are set to gain the most.
- 12/15/2021
|
3 Reasons to Add Accuray (ARAY) Stock to Your Portfolio
- Investors continue to be optimistic about Accuray (ARAY) owing to its slew of software upgrades.
- 12/03/2021
|
More Progress Evident At Accuray, But Sustainability And Follow-Through Remain Key
- Accuray's better than expected fiscal first quarter results underline ongoing progress in the story. Focused R&D efforts have significantly upgraded the capabilities and appeal of Accuray's systems, particularly on the software side.
- 11/30/2021
|
After Golden Cross, Accuray (ARAY)'s Technical Outlook is Bright
- Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
- 11/25/2021
|
Earnings Estimates Rising for Accuray (ARAY): Will It Gain?
- Accuray (ARAY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
- 11/17/2021
|
Here's What Could Help Accuray (ARAY) Maintain Its Recent Price Strength
- If you are looking for stocks that are well positioned to maintain their recent uptrend, Accuray (ARAY) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
- 11/17/2021
|
3 Penny Stocks To Add to Your Watchlist This Month November
- Are these penny stocks on your watchlist? The post 3 Penny Stocks To Add to Your Watchlist This Month November appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 11/06/2021
|
Accuray (ARAY) Q1 Earnings Beat Estimates, Margins Down
- Accuray (ARAY) registers growth in both Service and Product revenues during fiscal Q1.
- 11/04/2021
|
Accuray Incorporated (ARAY) CEO Josh Levine on Q1 2022 Results - Earnings Call Transcript
- Accuray Incorporated (ARAY) CEO Josh Levine on Q1 2022 Results - Earnings Call Transcript
- 11/03/2021
|
Accuray to Report First Quarter Fiscal 2022 Financial Results on November 3, 2021
- SUNNYVALE, Calif., Oct. 13, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the first quarter of fiscal year 2022, ended September 30, 2021, after the market close on Wednesday, November 3, 2021.
- 10/13/2021
|
Accuray (ARAY), C-RAD Ink Deal to Enhance Breast Cancer Treatment
- Accuray's (ARAY) latest agreement is likely to improve breast cancer treatment.
- 10/12/2021
|
Accuray to Host ASTRO Analyst & Investor Meeting on October 25, 2021
- SUNNYVALE, Calif., Oct. 12, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company will host an Analyst & Investor Meeting on Monday, October 25, 2021, in conjunction with the American Society of Radiation Oncology (ASTRO) Annual Meeting.
- 10/12/2021
|
French Hospital Network Unicancer Acquires Multiple Accuray Radixact® Systems with the ClearRT™ Helical Fan-Beam kVCT Imaging and Synchrony® Technologies
- SUNNYVALE, Calif., Sept. 29, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Unicancer has selected three Radixact ® Systems with the ClearRT ™ helical fan-beam kVCT imaging and Synchrony ® real-time delivery adaptation technologies to further their goal of providing truly personalized care to every cancer patient.
- 09/29/2021
|
Accuray's (ARAY) CyberKnife Favored For Prostate Cancer Treatment
- Per the PACE trial data, patients treated with Accuray's (ARAY) CyberKnife SBRT are likely to experience lesser bladder-related side effects unlike conventional linear accelerator.
- 09/15/2021
|
Accuray CyberKnife® Robotic Radiotherapy Platform is Superior to Conventional Linear Accelerators in Reducing Incidence of Bladder Side Effects in Prostate Cancer Patients
- SUNNYVALE, Calif., Sept. 14, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that data from the PACE – Prostate Advances in Comparative Evidence – trial indicate the company's CyberKnife ® robotic radiotherapy platform is superior to conventional linear accelerators in reducing the incidence of late grade two or higher bladder toxicity associated with prostate cancer stereotactic body radiation therapy (SBRT) treatments.
- 09/14/2021
|
Why Is Accuray (ARAY) Down 3.4% Since Last Earnings Report?
- Accuray (ARAY) reported earnings 30 days ago. What's next for the stock?
- 09/11/2021
|
Mika Nishimura Joins Accuray Board of Directors
- SUNNYVALE, Calif., Aug. 23, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the appointment of Mika Nishimura to the company's Board of Directors, effective as of August 17, 2021.
- 08/23/2021
|
Accuray Incorporated (ARAY) CEO Josh Levine on Q4 2021 Results - Earnings Call Transcript
- Accuray Incorporated (ARAY) CEO Josh Levine on Q4 2021 Results - Earnings Call Transcript
- 08/11/2021
|
Accuray (ARAY) Reports Q4 Loss, Tops Revenue Estimates
- Accuray (ARAY) delivered earnings and revenue surprises of 0.00% and 9.14%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/11/2021
|
Accuray (ARAY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
- Accuray (ARAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 08/04/2021
|
Hong Kong Sanatorium & Hospital Transforms Cancer Care in Asia with Treatment of First Patient Using the Accuray Radixact® System and ClearRT™ Helical Fan-Beam kVCT Imaging
- SUNNYVALE, Calif., July 22, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the medical care team at Hong Kong Sanatorium & Hospital (HKSH) in Hong Kong treated the first cancer patient in Asia using the Radixact ® System, the next-generation TomoTherapy ® platform, with ClearRT™ helical fan-beam kVCT imaging.
- 07/22/2021
|
Beloved Family Pet's Lung Cancer is Treated with Targeted Radiotherapy Using the Accuray Radixact® System with Synchrony® Technology
- SUNNYVALE, Calif., June 24, 2021 /PRNewswire/ -- The University of Wisconsin-Madison (UW-Madison) School of Veterinary Medicine team is advancing cancer care as the first to treat an animal using the Radixact® System with Synchrony ®.
- 06/24/2021
|
Accuray Announces Promotion of Suzanne Winter to President
- SUNNYVALE, Calif., June 22, 2021 /PRNewswire/ -- Accuray (NASDAQ: ARAY) announced today that Suzanne Winter has been promoted to president, effective as of July 1, 2021.
- 06/22/2021
|
Accuray's (ARAY) CyberKnife Gets Support From RayStation TPS
- Accuray (ARAY) introduces RayStation treatment planning support for CyberKnife Radiotherapy System and other radiation therapy devices.
- 06/18/2021
|
Accuray Expands CyberKnife® System Versatility with Integration of RaySearch's RayStation Treatment Planning System
- SUNNYVALE, Calif., June 16, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the launch of RayStation* treatment planning support for the company's CyberKnife® M6™** and S7™** Robotic, Radiotherapy Systems.
- 06/16/2021
|
Accuray (ARAY) Expands Commercialization of CE-Marked ClearRT
- Accuray's (ARAY) ClearRT imaging capability, which is now widely available following receipt of the CE Mark, offers better precision and accuracy in radiation therapy.
- 06/14/2021
|
Accuray Expands Commercialization of ClearRT™ Helical Fan-Beam kVCT Imaging for the Radixact® System with CE Mark Certification
- SUNNYVALE, Calif., June 10, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the company has received CE Mark certification for its ClearRT™ helical fan-beam kVCT imaging capability.
- 06/10/2021
|
More 'Hurry Up And Wait' For Accuray, But The China Opportunity Is Coming Through
- Accuray's fiscal third quarter was a little better than expected, but the lack of strong order momentum and/or upgraded guidance from management has tempered investor enthusiasm.
- 06/08/2021
|
Accuray (ARAY) Down 13.1% Since Last Earnings Report: Can It Rebound?
- Accuray (ARAY) reported earnings 30 days ago. What's next for the stock?
- 05/27/2021
|
Here's Why You Should Retain Accuray (ARAY) Stock for Now
- Investors continue to be optimistic about Accuray (ARAY) owing to its slew of regulatory approvals and strength in its TomoTherapy platform.
- 05/25/2021
|
Accuray Announces New $120 Million Credit Facility
- SUNNYVALE, Calif., May 6, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today announced it has entered into a new five-year $80 million term loan and $40 million revolving credit facility with Silicon Valley Bank and a syndicate of banks (the "New Credit Facility").
- 05/06/2021
|
Accuray Announces Convertible Notes Exchange and Subscription
- SUNNYVALE, Calif., May 6, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today announced that it has entered into privately negotiated agreements with the holders of its existing 3.75% senior convertible notes due 2022 (the "2022 Notes") to exchange an aggregate of $82.1 million principal amount of 2022 Notes for approximately $97.1 million aggregate principal amount of a new series of 3.75% senior convertible notes due 2026 (the "New Notes" and such transaction, the "Exchange").
- 05/06/2021
|
Accuray Incorporated Reports Inducement Awards Under NASDAQ Listing Rules
- SUNNYVALE, Calif., May 6, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported, as required by NASDAQ Listing Rules, equity inducement awards to Jean-Philippe Pignol, M.D.
- 05/06/2021
|
Geisinger becomes first in U.S. to treat cancer patients with Accuray Synchrony® technology on the Radixact® and CyberKnife® S7™ Systems to better target radiation treatments
- WILKES-BARRE, Pa. and SUNNYVALE, Calif.
- 05/03/2021
|
New Strong Sell Stocks for April 30th
- ARAY, EBS, FARM, SHLX, and TPB have been added to the Zacks Rank #5 (Strong Sell) List on April 30, 2021
- 04/30/2021
|
Accuray Customers Achieve Top Scores in AAPM MArkerless Lung Target Tracking CHallenge (MATCH) Using Synchrony® Technology on the Radixact® and CyberKnife® Systems
- SUNNYVALE, Calif., April 29, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Accuray customers took the top two positions in the MArkerless Lung Target Tracking CHallenge (MATCH) experimental branch using the Accuray Synchrony Lung Tracking with Respiratory Modeling on the Radixact® next-generation TomoTherapy® platform, and CyberKnife® System, respectively.
- 04/29/2021
|
Accuray's (ARAY) CEO Josh Levine on Q3 2021 Results - Earnings Call Transcript
- Accuray's (ARAY) CEO Josh Levine on Q3 2021 Results - Earnings Call Transcript
- 04/27/2021
|
Accuray Reports Third Quarter Fiscal 2021 Financial Results
- SUNNYVALE, Calif., April 27, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported its financial results for the third quarter of fiscal 2021 ended March 31, 2021.
- 04/27/2021
|
Accuray Receives Shonin Approval for ClearRT™ Helical kVCT Imaging, CE Mark Expected by End of June; Expands Commercial Launch
- SUNNYVALE, Calif., April 22, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the innovative ClearRT™ helical fan-beam kVCT imaging* capability has now been in clinical use for over two months, and is on track to expand into other markets.
- 04/22/2021
|
Accuray to Report Third Quarter Fiscal 2021 Financial Results on April 27, 2021
- SUNNYVALE, Calif., April 13, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the third quarter of fiscal year 2021, ended March 31, 2021, after the market close on Tuesday April 27, 2021.
- 04/13/2021
|
Accuray Appoints Healthcare Executive and Physician Byron C. Scott to Board of Directors
- SUNNYVALE, Calif., Feb. 19, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the appointment of Byron C. Scott, M.D., MBA to the company's Board of Directors, effective as of February 12, 2021. Dr. Scott brings significant experience as a physician executive with...
- 02/19/2021
|
Accuray to Participate in BTIG's Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference
- SUNNYVALE, Calif., Feb. 5, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today announced its participation in BTIG's Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference. The management team is scheduled to participate in a Fireside Chat on Thursday,...
- 02/05/2021
|
Accuray Is Seeing Green Shoots For Its Large China Opportunity
- Accuray announced better than expected fiscal Q2 results, with the first revenue from its China Type A license backlog. Orders remain erratic, but the backlog was up 11% yoy and stable sequentially, and management is making investment decisions that appear to signal meaningful future growth.
- 01/28/2021
|
Accuray Incorporated (ARAY) CEO Josh Levine on Q2 2021 Results - Earnings Call Transcript
- Accuray Incorporated (ARAY) CEO Josh Levine on Q2 2021 Results - Earnings Call Transcript
- 01/27/2021
|
Accuray (ARAY) Beats Q2 Earnings and Revenue Estimates
- Accuray (ARAY) delivered earnings and revenue surprises of 600.00% and 4.96%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 01/27/2021
|
10 Stocks Under $10 to Buy Before They Soar
- One of the counterintuitive dynamics of the pandemic-disrupted year in 2020 was the rise of Wall Street. But that doesn't mean you've missed the boat, as these stocks under $10 demonstrate.
- 01/27/2021
|
Accuray (ARAY) Releases Encouraging Breast Cancer Study Results
- Accuray (ARAY) releases positive data from a prospective trial of 338 women with low-risk breast cancer.
- 01/26/2021
|
Seven-year Data Shows Accuray TomoTherapy® System Provides Excellent Long-Term Control of Low-Risk Breast Cancer
- SUNNYVALE, Calif., Jan. 19, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that data from a prospective, phase II trial of 338 women with low-risk breast cancer showed 98.8 percent had local disease control seven years after receiving once-daily accelerated...
- 01/19/2021
|
Accuray to Report Second Quarter Fiscal 2021 Financial Results on January 27, 2021
- SUNNYVALE, Calif., Jan. 8, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the second quarter of fiscal year 2021, ended December 31, 2020, after the market close on Wednesday January 27, 2021. Management will host a conference call to review the...
- 01/08/2021
|
Accuray (ARAY) Gets 510(k) Nod for ClearRT in TomoTherapy
- Accuray (ARAY) new innovative imaging solution is designed to provide cost effective and exceptional diagnostic quality image.
- 01/06/2021
|
Accuray To Participate at J.P. Morgan's 39th Annual Healthcare Conference
- SUNNYVALE, Calif., Jan. 6, 2021 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) today announced its participation in the 39th J.P. Morgan Annual Healthcare Conference. Josh Levine, President and CEO, is scheduled to present on Thursday, January 14, 2021 at 11:00 am PACIFIC / 2:00 pm...
- 01/06/2021
|
Accuray Receives 510(k) FDA Clearance for ClearRT™ Helical kVCT Imaging for the Radixact® Treatment Delivery System
- SUNNYVALE, Calif., Jan. 5, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its ClearRT™ Helical kVCT Imaging* for the Radixact® System, the next generation...
- 01/05/2021
|
8 Cheap Stocks to Snap Up for the New Year
- This year has been a remarkable one for cheap stocks, many of which have enjoyed contrarian upside. However, there are still more opportunities to be had for the intrepid speculator.
- 01/04/2021
|
Here's Why You Must Add Accuray (ARAY) to Your Portfolio Now
- Investor confidence is high on Accuray (ARAY) stock, courtesy of its solid prospects.
- 12/29/2020
|
Accuray and DHL Supply Chain establish global service logistics platform to support delivery of advanced cancer treatment technology
- SUNNYVALE, Calif. and WESTERVILLE, Ohio, Nov. 18, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) and DHL Supply Chain announced today they have entered into a global service parts logistics partnership that will further strengthen the Accuray aftermarket supply chain and expand...
- 11/18/2020
|
Amid COVID-19 Pressures, Accuray Looks Toward The Start Of Its China Ramp
- Fiscal first quarter revenue was a little better than expected, and management did well on costs, achieving a modest profit where a modest loss had been expected. Orders were down, not surprising given the challenges/pressures from COVID-19, but the backlog remains significant and Accuray should start recognizing Type A system revenue in China this quarter.
- 11/01/2020
|
Accuray Incorporated (ARAY) CEO Josh Levine on Q1 2021 Results - Earnings Call Transcript
- Accuray Incorporated (ARAY) CEO Josh Levine on Q1 2021 Results - Earnings Call Transcript
- 10/29/2020
|
Global Healthcare Robotics Market (2020 to 2025) - by Type, Product, Application, End-user, Region, Competition, Forecast & Opportunities - ResearchAndMarkets.com
|
Radiation Therapy Market Size 2020 Growing Rapidly with Modern Trends, Development Status, Investment Opportunities, Share, Revenue, Demand and Forecast to 2026 Says Industry Research Biz
- Oct 06, 2020 (The Expresswire) --
"Final Report will add the analysis of the impact of COVID-19 on this industry." Global “Radiation Therapy Market” Research...
- 10/06/2020
|
Worldwide Medical Radiation Detection, Monitoring & Safety Industry to 2025 - Featuring Fortive, Mirion Technologies & IBA Worldwide Among Others - ResearchAndMarkets.com
|
United States Radiation Oncology Market Size, Share & Trends Analysis Report, 2020-2027 - ResearchAndMarkets.com
|
Accuray Incorporated : INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) | MarketScreener
|
Here’s What’s Happening With Returns At Accuray (NASDAQ:ARAY)
- There are a few key trends to look for if we want to identify the next multi-bagger. Amongst other things, we'll want...
- 08/17/2020
|
Accuray Inc (ARAY) Q4 2020 Earnings Call Transcript
- Welcome to Accuray's conference call to review financial results for the fourth quarter of fiscal year 2020, which ended on June 30, 2020. During our call this afternoon, management will review recent corporate developments.
- 08/14/2020
|
Accuray Idling On The Runway Ahead Of A Significant Chinese Revenue Launch
- Accuray came in a little better than expected this quarter, but COVID-19 has pushed product revenue back to levels not seen since FY 2013.
- 08/14/2020
|
Accuray (ARAY) Reports Loss in Q4, Revenues Miss Estimates
- Accuray (ARAY) registered decline in Product and Service revenues in Q4
- 08/14/2020
|
Accuray Incorporated (ARAY) CEO Joshua Levine on Q4 2020 Results - Earnings Call Transcript
- Accuray Incorporated (NASDAQ:ARAY) Q4 2020 Results Earnings Conference Call August 13, 2020, 04:30 PM ET Company Participants Joseph Diaz - Managing Partner, Lytham Partners Joshua Levine - President & CEO Shigeyuki Hamamatsu - SVP & CFO Suzanne Winter - Chief Commercial Officer & Head of R&D Conference Call Participants Josh Jennings - Cowen Brooks O'Neil - Lake Street Capital Markets Presentation Operator Good afternoon.
- 08/13/2020
|
Recap: Accuray Q4 Earnings
- Shares of Accuray (NASDAQ:ARAY) rose 1.66% in after-market trading after the company reported Q4 results.Quarterly Results Earnings per share rose 100.00% year over year to ($0.00), which beat the estimate of ($0.02).Revenue of $94,977,000 decreased by 19.11% from the same period last year, which beat the estimate of $91,560,000.Looking Ahead Accuray hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.Conference Call Details Date: Aug 13, 2020View more earnings on ARAYTime: 04:30 PMET Webcast URL: https://www.webcaster4.com/Webcast/Page/2330/35923Technicals 52-week high: $4.6852-week low: $1.33Price action over last quarter: Up 12.71%Company Profile Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, innovative treatment solutions which set the standard of radiation therapy care with the aim of helping patients live better lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention. CyberKnife Systems requires no anesthesia, and treatment sessions are done on an outpatient basis.See more from Benzinga * Earnings Scheduled For August 13, 2020 * Accuray's Earnings Outlook(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 08/13/2020
|
Accuray Reports Fourth Quarter and Fiscal 2020 Financial Results
- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal year ended June 30, 2020.
- 08/13/2020
|
Accuray Incorporated 2020 Q4 - Results - Earnings Call Presentation
|
Accuray's Earnings Outlook
- On Thursday, August 13, Accuray (NASDAQ: ARAY) will release its latest earnings report. Check out Benzinga's preview to understand the implications.Earnings and Revenue Sell-side analysts are expecting Accuray's earnings per share to be near $-0.02 on sales of $91.56 million. In the same quarter last year, Accuray reported EPS of $-0.02 on revenue of $117.42 million. If the company were to match the consensus estimate when it reports Thursday, earnings would not change. Here's how the company's reported EPS has stacked up against analyst estimates in the past:Quarter Q3 2020 Q2 2020 Q1 2019 Q4 2019 EPS Estimate -0.04 -0.07 -0.09 0.01 EPS Actual 0.03 -0.02 -0.11 -0.02 Revenue Estimate 97.26 M 97.73 M 92.15 M 116.37 M Revenue Actual 99.55 M 98.83 M 89.58 M 117.42 M Stock Performance Over the last 52-week period, shares are down 11.44%. Given that these returns are generally negative, long-term shareholders are probably unhappy going into this earnings release.View more earnings on ARAYDon't be surprised to see the stock move on comments made during its conference call. Accuray is scheduled to hold the call at 16:30:00 ET and can be accessed here: https://www.webcaster4.com/Webcast/Page/2330/35923See more from Benzinga * Preview: Myriad Genetics's Earnings * Earnings Outlook For II-VI * Earnings Outlook for iQIYI(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 08/12/2020
|
Accuray Incorporated (NASDAQ:ARAY) Shares Purchased by State Street Corp
- State Street Corp increased its position in shares of Accuray Incorporated (NASDAQ:ARAY) by 4.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,672,496 shares of the medical equipment provider’s stock after acquiring an additional 72,267 shares during the period. […]
- 08/09/2020
|
Accuray (ARAY) Earnings Expected to Grow: Should You Buy?
- Accuray (ARAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 08/06/2020
|
ValuEngine Downgrades Accuray (NASDAQ:ARAY) to Hold
- Accuray (NASDAQ:ARAY) was downgraded by equities research analysts at ValuEngine from a “buy” rating to a “hold” rating in a report issued on Monday, ValuEngine reports. A number of other analysts also recently commented on ARAY. BTIG Research reissued a “buy” rating and issued a $6.00 price objective on shares of Accuray in a research […]
- 08/05/2020
|
Anne B. Le Grand Joins Accuray Board of Directors
- Accuray Incorporated (NASDAQ: ARAY) announced today the appointment of Anne B. Le Grand to the company's Board of Directors, effective as of July 16, 2020. In addition, she will serve on the Board's Nominating and Corporate Governance Committee. With Ms. Le Grand's appointment, the Accuray Board will consist of nine members.
- 07/22/2020
|
Accuray To Report Fiscal Year-end 2020 Financial Results on August 13, 2020
- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the fourth quarter and the 2020 fiscal year, ended June 30, 2020 after the market close on Thursday, August 13, 2020. Management will host a conference call to review the results at 1:30 p.m. PT / 4:30 p.m. ET on the same day.
- 07/16/2020
|
HighTower Advisors LLC Makes New Investment in Accuray Incorporated (NASDAQ:ARAY)
- HighTower Advisors LLC acquired a new position in Accuray Incorporated (NASDAQ:ARAY) in the 1st quarter, HoldingsChannel reports. The firm acquired 15,000 shares of the medical equipment provider’s stock, valued at approximately $29,000. A number of other hedge funds and other institutional investors have also added to or reduced their stakes in ARAY. US Bancorp DE […]
- 07/12/2020
|
Diversified Trust Co Purchases Shares of 15,183 Accuray Incorporated (NASDAQ:ARAY)
- Diversified Trust Co bought a new position in shares of Accuray Incorporated (NASDAQ:ARAY) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 15,183 shares of the medical equipment provider’s stock, valued at approximately $31,000. Several other hedge funds have also recently bought and sold shares […]
- 07/12/2020
|
Based On Its ROE, Is Accuray Incorporated (NASDAQ:ARAY) A High Quality Stock?
- Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
- 07/07/2020
|
Hedge Funds Are Selling Accuray Incorporated (ARAY)
- The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of March 31st, 2020. […]
- 06/28/2020
|
Coronavirus Spurs Growth for 3 Robotics-Assisted Surgery Stocks
- In the face of the pandemic, the robotics-assisted surgery space continues to thrive on a slew of positive developments.
- 06/25/2020
|
Surgical Robots Market Trajectory & Analytics to 2027 with the Potential Impact of COVID-19 - ResearchAndMarkets.com
|
RaySearch Laboratories publ : Axim Nuclear & Oncology to supply RaySearch systems to South African radiotherapy market | MarketScreener
|
3 “Strong Buy” Penny Stocks With Explosive Upside Potential
- When searching for explosive risk/reward plays, look no further than penny stocks. These names trading for under $5 per share are considered to be some of the most controversial on the Street, and divide market watchers into two factions: critics and fans.The former brings a valid argument to the table. Stocks don’t just end up trading at such low levels; typically, there’s a very real reason for their bargain price tags. This can be weak fundamentals or headwinds that are too strong to overcome.As for the latter, the potential for an investment worth only pocket change to appreciate even a seemingly insignificant amount, the result of which could be massive percentage gains, is too enticing to ignore. Not to mention the low share price means you can carve out a bigger stake for less money upfront.The implication for investors? Due diligence is essential, as some penny stocks might not have what it takes to climb their way back up.Taking all of this into consideration, we used TipRanks’ database to pinpoint three penny stocks in the healthcare sector with promising long-term growth prospects. Each gets a thumbs up from the analyst community, scoring a “Strong Buy” consensus rating, and boasts huge upside potential. We are talking returns of at least 100% over the next months.Accuray Inc. (ARAY)With its cutting-edge CyberKnife S7 System, Accuray provides both practices and clinicians with the capabilities to deliver personalized stereotactic radiosurgery (SRS), stereotactic body radiotherapy (SBRT) and hypofractionated radiotherapy treatments. Given its $2.28 share price, some believe that now is the ideal time to get on board.Cowen analyst Joshua Jennings acknowledges that COVID-19 has brought about strong headwinds for the radiation oncology space as a whole, with multiple hospitals re-prioritizing their capital equipment purchasing plans. Yet, the analyst’s bullish thesis on ARAY remains very much intact, with Jennings arguing that the rebound should be the focus here. He calls for sequential improvements throughout fiscal 2021.Expounding on this, Jennings stated, “We believe the company is well-positioned to weather the storm and capitalize on its longer-term opportunities. ARAY has multiple attractive growth drivers that will kick back in during normalized periods. Its strategic standing in China, combined with its replacement cycle prospects and overall radiation oncology market dynamics, fuels our optimistic outlook for a sequential recovery trajectory in fiscal 2021 and the return to growth in fiscal 2022 (off of a pre-COVID-19 revenue run rate).”"We would highlight that ARAY shares remain deeply discounted at under 0.7x forward sales and represent an attractive value proposition considering the company was on track to deliver an 8-12% revenue CAGR prior to the COVID-19 crisis," the analyst added.To this end, Jennings rates ARAY an Outperform (i.e. Buy) along with an $8.00 price target. Should this target be met, a twelve-month gain of 250% could be in store. (To watch Jennings’ track record, click here) Like Jennings, other analysts also take a bullish approach. ARAY's Strong Buy consensus rating breaks down into 3 Buy ratings received in the last three months. Additionally, the $8 average price target matches Jennings’. (See ARAY stock analysis on TipRanks)Ziopharm Oncology (ZIOP)Utilizing the body’s immune response, Ziopharm Oncology develops immuno-oncology gene and cell therapies to fight blood cancers and solid tumors. Based on its latest data readout and $3.27 share price, it’s no wonder this name is on Wall Street’s radar.Recently, ZIOP released data on its controlled IL-12 program in monotherapy and combination in glioblastoma (GBM). Writing for Cantor, 5-star analyst Alethia Young believes both the monotherapy and combination results support the promising efficacy trends that were already seen. Also encouraging, she highlights the fact that the “monotherapy study survival data (now fairly mature) clearly support further development.”Looking more closely at the survival data, in a subgroup of 20 patients that were given low-dose steroids and unifocal disease, 16.2 months of median survival were witnessed, with the mean follow up landing at 14.1 months. As Young was expecting to see mean survival come in at 6-12 months, she is optimistic about the program’s potential.As for the combination portion, even though “median follow was shorter than monotherapy at 8.3 months,” Young pointed out, “IL-12 helps put T cells into the tumor, which could create PD-1 on the surface receptor, suggesting that adding PD-1 could be synergistic by turning cold tumors (little immune activity) into hot ones.”To sum it all up, Young commented, “Refractory GBM remains an area of high unmet need. Importantly, we also think either monotherapy or combination provide shots on goal to improve the standard of care. So far, the safety has looked good in the main study as well.”It should be noted that the IL-12 and GBM space has faced challenges in the past, which has contributed to the skepticism surrounding ZIOP’s pipeline. However, everything that the company has going for it prompted Young to stay with the bulls. Along with an Overweight rating, she left her price target at $6. This figure implies shares could climb 83% higher in the next year. (To watch Young’s track record, click here) All in all, other analysts are on the same page. 4 Buys and no Holds or Sells add up to a Strong Buy consensus rating. Based on the $6.50 average price target, which is more aggressive than Young’s, the upside potential comes in at 99%. (See Ziopharm stock analysis on TipRanks)Entasis Therapeutics (ETTX)Last but not least we have Entasis Therapeutics, which develops molecules that could potentially address and overcome mechanisms of antibiotic resistance in specific bacterial pathogens. Currently going for $2.98 apiece, several members of the Street believe that its share price reflects an attractive entry point.ETTX is slated to release topline data for its Phase 3 ATTACK study, which is evaluating SUL-DUR (ETX2514SUL), a fixed-dose combination of the broad-spectrum beta-lactamase inhibitor ETX2514 with sulbactam, as a treatment for patients with pneumonia or bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. COVID-19 has had an impact on the study’s enrollment, but Wedbush analyst Robert Driscoll remains squarely in the bull camp, pointing out that efforts have been made to limit the impact on the trial timeline.Driscoll added, “We expect enrollment will be more rapid once sites China open recruitment – ETTX’s partner Zai Labs is co-enrolling up to 20% of the patients in ATTACK, which will likely allow for approval in China should ATTACK be successful. We believe the study has a high chance of success given demonstrated in vitro activity against a panel of Acinetobacter strains, dose proportional PK in healthy volunteers within the predicted therapeutic range, and a BAL study showing equivalent lung penetration for SUL-DUR to avibactam (approved for HABP/ VAP in combination with ceftazidime).”Along with this, Phase 2 data demonstrated SUL-DUR was generally well tolerated in cUTI patients. It also didn’t produce serious adverse events, with the adverse event profile resembling the placebo/IMI arm.It should be noted that the ongoing Phase 3 uncomplicated gonorrhea study has been temporarily suspended. However, Driscoll tells clients that topline data is still set for publication in 2H:21. Speaking to the potential opportunity, he said, “Phase 2 data, published in NEJM, demonstrated 100% success rate for 47 urogenital gonorrhea patients treated with 3 g zoliflodacin vs. 100% patients treated with an intramuscular injection of ceftriaxone. We see a significant opportunity for ETTX given the lack of recommended oral antibiotics as an alternative to intramuscular administered ceftriaxone, which is currently the only recommended option.”As the recent private placement could raise $31.7 million and extend its cash runway into the middle of 2021, Driscoll likes what he’s seeing. To this end, he maintained an Outperform (i.e. Buy) rating along with a $7 price target, which leaves room for shares to skyrocket 135% in the next twelve months. (To watch Driscoll’s track record, click here) Do other analysts agree with Driscoll? They do. Only Buy ratings, 4, in fact, have been issued in the last three months, so the consensus rating is a Strong Buy. At $6.25, the average price target puts the potential twelve-month gain at 110%. (See ETTX stock-price forecast on TipRanks)To find good ideas for penny stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
- 06/22/2020
|
Assessment of COVID-19's Effect on Head and Neck Cancer Diagnostics Market 2020-2024 | Increasing Cancer Research Across the World to Augment Growth | Technavio
- The Global Head and Neck Cancer Diagnostics Market will grow by USD 3.41 bn during 2020-2024
- 06/19/2020
|
Accuray's New CyberKnife S7 System to Boost Patient Care
- Accuray's (ARAY) newly launched CyberKnife S7 System will enable clinicians to provide best possible care to their patients through new capabilities.
- 06/18/2020
|
Accuray (NASDAQ:ARAY) Given Buy Rating at BTIG Research
- Accuray (NASDAQ:ARAY)‘s stock had its “buy” rating reaffirmed by analysts at BTIG Research in a report released on Wednesday, TipRanks reports. They currently have a $6.00 target price on the medical equipment provider’s stock. BTIG Research’s target price would suggest a potential upside of 165.49% from the company’s previous close. Several other research analysts have […]
- 06/18/2020
|
Accuray Launches New CyberKnife® S7™ System
- Accuray Incorporated (NASDAQ: ARAY) announced today the company has launched the CyberKnife® S7™ System, an innovative device combining speed, advanced precision, and real-time artificial intelligence (AI)-driven motion tracking and synchronization treatment delivery for all stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) treatments — in as little as 15 minutes. The CyberKnife S7 System is the next-generation CyberKnife platform, a robotic, non-invasive radiation therapy device capable of treating cancerous and benign tumors throughout the body, as well as neurologic disorders. The new CyberKnife technology is the most recent illustration of Accuray innovation in radiation therapy that empowers healthcare providers through new capabilities to provide the best possible care to their patients.
- 06/17/2020
|
Here's Why You Should Add Accuray to Your Portfolio Now
- Investor confidence is high on Accuray (ARAY) stock, thanks to solid prospects.
- 06/01/2020
|
Why Is Accuray (ARAY) Down 9.2% Since Last Earnings Report?
- Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- 05/28/2020
|
Why Is Accuray (ARAY) Down 9.2% Since Last Earnings Report?
|
Accuray Synchrony® Real-time Adaptive Technology for the Radixact® System Wins 2020 MedTech Breakthrough Award
- Accuray Incorporated (NASDAQ: ARAY) today announced that MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global health and medical technology market, has selected the Accuray Synchrony® Real-time Adaptive Technology for the Radixact® System as the winner of its "Best Overall Medical Device Solution" award in the fourth annual MedTech Breakthrough Awards program.
- 05/19/2020
|
6 Stocks to Benefit From the 'New Normal'
|
Delivery Robots Making an Impression Amid Coronavirus Pandemic
- Since the coronavirus outbreak, robots have filled up several job vacancies caused by social distancing orders. Here are five robotics and related stocks investors should closely watch.
- 05/14/2020
|
Radiation Therapy Market with Focus on LINAC: Insights & Forecast with Potential Impact of COVID-19 (2020-2024) - ResearchAndMarkets.com
|
Robotic Surgical Procedures Market | 2020 Size, Share Estimation, Growth Rate, Products, Leading Players, Competitive Analysis, Regional And Global Industry Trends Forecast To 2026
- May 11, 2020 (The Expresswire) --
Report segments Robotic Surgical Procedures Market By Product Type (Gynecology, Urology, General Surgery, Orthopedics and...
- 05/11/2020
|
Edited Transcript of ARAY earnings conference call or presentation 28-Apr-20 8:30pm GMT
- Q3 2020 Accuray Inc Earnings Call
- 05/09/2020
|
Edited Transcript of ARAY earnings conference call or presentation 28-Apr-20 8:30pm GMT
- Q3 2020 Accuray Inc Earnings Call
- 05/08/2020
|
How Accuray (ARAY) Stock Stands Out in a Strong Industry
- Accuray (ARAY) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- 05/07/2020
|
Does Accuray Incorporated's (NASDAQ:ARAY) CEO Pay Compare Well With Peers?
- Joshua Levine has been the CEO of Accuray Incorporated (NASDAQ:ARAY) since 2012. This report will, first, examine the...
- 05/03/2020
|
Accuray Incorporated Just Reported A Surprise Profit And Analysts Updated Their Estimates
- Shareholders will be ecstatic, with their stake up 24% over the past week following Accuray Incorporated's...
- 05/03/2020
|
Will Accuray (ARAY) Gain on Rising Earnings Estimates?
- Accuray (ARAY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
- 05/01/2020
|
What Makes Accuray (ARAY) a New Strong Buy Stock
- Accuray (ARAY) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 05/01/2020
|
New Strong Buy Stocks for May 1st
- Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today.
- 05/01/2020
|
New Strong Buy Stocks for May 1st
|
108 Biggest Movers From Yesterday
- Gainers
Capricor Therapeutics, Inc. (NASDAQ: CAPR) shares jumped 252.7% to close at $8.50 on Wednesday after the company reported that its new data from study of 6 critically-ill...
- 04/30/2020
|
BTIG Maintains a Buy Rating on Accuray (ARAY)
- In a report released today, Marie Thibault from BTIG maintained a Buy rating on Accuray (ARAY), with a price target of $6.00. The company's shares closed
- 04/29/2020
|
BTIG Maintains a Buy Rating on Accuray (ARAY)
- In a report released today, Marie Thibault from BTIG maintained a Buy rating on Accuray (ARAY – Research Report), with
- 04/29/2020
|
82 Stocks Moving In Wednesday's Mid-Day Session
- Gainers
Capricor Therapeutics, Inc. (NASDAQ: CAPR) shares climbed 138.2% to $5.74 after the company reported that its new data from study of 6 critically-ill coronavirus patients...
- 04/29/2020
|
Accuray (ARAY) Earnings and Revenues Beat Estimates in Q3
- Accuray's (ARAY) gross orders were driven by solid EMEA momentum in Q3.
- 04/29/2020
|
Accuray (ARAY) Earnings and Revenues Beat Estimates in Q3
- Accuray's (ARAY) gross orders were driven by solid EMEA momentum in Q3.
- 04/29/2020
|
GOOGL, CHK among premarket gainers
- Spark Networks SE (NYSEMKT:LOV) +38% on 2H results.Chimerix (NASDAQ:CMRX) +29% on launch of DSTAT study in COVID-19.resTORbio (NASDAQ:TORC) +24% on merger with Adicet BioR. R. Donnelley & Sons (NY
- 04/29/2020
|
Accuray shares are trading higher after the company reported better-than-expected Q3 EPS and sales results.
|
16 Healthcare Stocks Moving In Wednesday's Pre-Market Session
- Gainers
• Chimerix, Inc. (NASDAQ:CMRX) shares increased by 38.41% to $2.09 during Wednesday's pre-market session.
• Accuray, Inc. (NASDAQ:ARAY) shares increased by...
- 04/29/2020
|
35 Stocks Moving in Wednesday's Pre-Market Session
- Gainers
Sify Technologies Limited (NASDAQ: SIFY) shares rose 59.4% to $1.69 in pre-market trading. Sify Technologies is expected to report its financial results for the full...
- 04/29/2020
|
IsoRay (NYSEAMERICAN:ISR) Cut to Hold at Zacks Investment Research
- IsoRay (NYSEAMERICAN:ISR) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Wednesday, Zacks.com reports. According to Zacks, “IsoRay, Inc. is a medical technology company that produces therapeutic radioactive isotopes. Through its subsidiary, IsoRay Medical, Inc., develops, manufactures and sells isotope-based medical products and devices […]
- 04/29/2020
|
Accuray Inc (ARAY) Q3 2020 Earnings Call Transcript
- Welcome to Accuray's conference call to review financial results for the third quarter of fiscal year 2020, which ended March 31, 2020. Joining us today are Josh Levine, Accuray's President and Chief Executive Officer; and Shig Hamamatsu, Accuray's Senior Vice President and Chief Financial Officer.
- 04/29/2020
|
Accuray (ARAY) Earnings and Revenues Beat Estimates in Q3
|
Accuray (ARAY) Beats Q3 Earnings and Revenue Estimates
- Accuray (ARAY) delivered earnings and revenue surprises of 200.00% and 3.21%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- 04/28/2020
|
23 Stocks Moving In Tuesday's After-Hours Session
- Gainers
Lattice Semiconductor (NASDAQ: LSCC) shares are trading higher after the company reported better-than-expected Q1 EPS results.
Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL...
- 04/28/2020
|
Accuray shares are trading higher after the company reported better-than-expected Q3 EPS and sales results.
|
Accuray Withradws Its FY20 Guidance Due To Coronavirus
|
Accuray Q3 EPS $0.030 Beats $(0.040) Estimate, Sales $99.500M Beat $97.260M Estimate
|
Accuray Reports Fiscal 2020 Third Quarter Financial Results
- Accuray Incorporated (NASDAQ: ARAY) today reported its financial results for the third quarter of fiscal 2020 ended March 31, 2020.
- 04/28/2020
|
IsoRay (NYSEAMERICAN:ISR) Upgraded to Buy by Zacks Investment Research
- IsoRay (NYSEAMERICAN:ISR) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Friday, Zacks.com reports. The firm currently has a $0.75 price objective on the healthcare company’s stock. Zacks Investment Research‘s target price indicates a potential upside of 20.23% from the […]
- 04/24/2020
|
The Global Surgical Robots Market is expected to grow from USD 5,423.13 Million in 2018 to USD 18,423.13 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 19.08%
- New York, April 23, 2020 -- Reportlinker.com announces the release of the report "Global Surgical Robots Market - Premium Insight, Competitive News Feed Analysis, Company.
- 04/23/2020
|
Bank of New York Mellon Corp Has $1.52 Million Stock Holdings in Accuray Incorporated (NASDAQ:ARAY)
- Bank of New York Mellon Corp cut its stake in Accuray Incorporated (NASDAQ:ARAY) by 12.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 539,865 shares of the medical equipment provider’s stock after selling 78,098 shares during the period. Bank of New […]
- 04/23/2020
|
Here's Why You Should Retain Accuray in Your Portfolio
- Investor confidence remains high in Accuray (ARAY) stock, thanks to solid prospects.
- 04/20/2020
|
Here's Why You Should Retain Accuray in Your Portfolio
- Investor confidence remains high in Accuray (ARAY) stock, thanks to solid prospects.
- 04/20/2020
|
Goldman Sachs Group Inc. Has $747,000 Holdings in Accuray Incorporated (NASDAQ:ARAY)
- Goldman Sachs Group Inc. decreased its holdings in shares of Accuray Incorporated (NASDAQ:ARAY) by 43.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 264,866 shares of the medical equipment provider’s stock after selling 203,065 shares during the quarter. Goldman […]
- 04/20/2020
|
Here's Why You Should Retain Accuray in Your Portfolio
|
Varian Medical price target lowered to $90 from $100 at JPMorgan VAR;ARAY
- Varian Medical price target lowered to $90 from $100 at JPMorgan JPMorgan VAR ARAY
- 04/17/2020
|
Accuray To Report Fiscal 2020 Third Quarter Financial Results on April 28, 2020
- Accuray Incorporated (NASDAQ: ARAY) will report results for its third quarter ended March 31, 2020 on Tuesday, April 28, 2020 after the market close. Management will host a conference call to review the results at 1:30 p.m. PT/4:30 p.m. ET on the same day.
- 04/16/2020
|
IsoRay (NYSEAMERICAN:ISR) Rating Lowered to Hold at Zacks Investment Research
- IsoRay (NYSEAMERICAN:ISR) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Wednesday, Zacks.com reports. According to Zacks, “IsoRay, Inc. is a medical technology company that produces therapeutic radioactive isotopes. Through its subsidiary, IsoRay Medical, Inc., develops, manufactures and sells isotope-based medical products and devices […]
- 04/15/2020
|
Veterinary Oncology Market Size Worth $447.0 Million by 2027: Grand View Research, Inc.
- The global veterinary oncology market size is expected to reach USD 447.0 million by 2027, expanding at a CAGR of 10.7% over the forecast period, according to a new report by Grand View Research, Inc. Increasing prevalence of cancer in pets and demand for veterinary diagnostics are projected to drive
- 04/07/2020
|
Comparing Glaukos (NYSE:GKOS) & Accuray (NYSE:ARAY)
- Glaukos (NYSE:GKOS) and Accuray (NASDAQ:ARAY) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, dividends, valuation and profitability. Volatility and Risk Glaukos has a beta of 1.7, suggesting that its stock price is 70% more […]
- 03/31/2020
|
Why You Should Invest in Cardinal Health (CAH) Stock Now
- Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment, diversified product portfolio and strategic buyouts.
- 03/30/2020
|
Why You Should Invest in Cardinal Health (CAH) Stock Now
- Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment, diversified product portfolio and strategic buyouts.
- 03/30/2020
|
Why You Should Invest in Cardinal Health (CAH) Stock Now
|
Here's Why You Should Invest in DaVita (DVA) Stock Right Now
- DaVita (DVA) continues to gain traction from strong international foothold, strategic buyout of dialysis centers and DaVita Kidney Care.
- 03/27/2020
|
Here's Why You Should Invest in DaVita (DVA) Stock Right Now
- DaVita (DVA) continues to gain traction from strong international foothold, strategic buyout of dialysis centers and DaVita Kidney Care.
- 03/27/2020
|
Here's Why You Should Hold On to PerkinElmer (PKI) Stock Now
- PerkinElmer (PKI) expects to witness foreign exchange headwinds in 2020.
- 03/26/2020
|
Here's Why You Should Hold On to PerkinElmer (PKI) Stock Now
- PerkinElmer (PKI) expects to witness foreign exchange headwinds in 2020.
- 03/26/2020
|
Here's Why You Should Hold On to Inogen (INGN) Stock for Now
- Inogen (INGN) expects to report a loss per share in the first quarter of 2020.
- 03/25/2020
|
Here's Why You Should Hold On to Inogen (INGN) Stock for Now
- Inogen (INGN) expects to report a loss per share in the first quarter of 2020.
- 03/25/2020
|
Here's Why You Should Retain Merit Medical (MMSI) Stock Now
- Merit Medical (MMSI) continues to benefit from growing product pipeline, strong R&D focus and strategic acquisitions.
- 03/24/2020
|
Here's Why Investors Should Buy Masimo (MASI) Stock Now
- Masimo (MASI) sees a slew of developments lately.
- 03/24/2020
|
Here's Why Investors Should Buy Masimo (MASI) Stock Now
- Masimo (MASI) sees a slew of developments lately.
- 03/24/2020
|
Masimo & University Hospitals Unite for Patient Monitoring
- Masimo (MASI) sees a plethora of developments lately.
- 03/24/2020
|
Masimo & University Hospitals Unite for Patient Monitoring
- Masimo (MASI) sees a plethora of developments lately.
- 03/24/2020
|
Here's Why You Should Retain Merit Medical (MMSI) Stock Now
|
PRA Health's New Program to Lend Support to Healthcare System
- PRA Health's (PRAH) COVID-19 Monitoring Program will allow individuals to connect with a healthcare professional remotely while maintaining social distancing.
- 03/23/2020
|
Here's Why You Should Hold on to NextGen Healthcare Stock Now
- NextGen Healthcare (NXGN) continues to benefit from growing RCM and EHR markets, and robust demand for other NextGen solutions.
- 03/23/2020
|
Here's Why You Should Hold on to NextGen Healthcare Stock Now
- NextGen Healthcare (NXGN) continues to benefit from growing RCM and EHR markets, and robust demand for other NextGen solutions.
- 03/23/2020
|
Masimo's Latest Buyout to Boost Respiratory Product Spectrum
- Masimo (MASI) expects the transaction to be neutral to 2020 earnings.
- 03/20/2020
|
Masimo's Latest Buyout to Boost Respiratory Product Spectrum
- Masimo (MASI) expects the transaction to be neutral to 2020 earnings.
- 03/20/2020
|
Here's Why You Should Hold Onto Baxter (BAX) Stock for Now
- Baxter (BAX) issues strong guidance for the first quarter of 2020.
- 03/19/2020
|
Here's Why You Should Hold Onto Baxter (BAX) Stock for Now
- Baxter (BAX) issues strong guidance for the first quarter of 2020.
- 03/19/2020
|
Accuray Enters Oversold Territory
- Accuray has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
- 03/19/2020
|
Accuray Enters Oversold Territory
|
Varian's (VAR) ProBeam Compact Treats First Patient at UAB
- Varian's (VAR) flagship ProBeam platform is seeing multiple developments of late.
- 03/18/2020
|
Varian's (VAR) ProBeam Compact Treats First Patient at UAB
- Varian's (VAR) flagship ProBeam platform is seeing multiple developments of late.
- 03/18/2020
|
NextGen's New Platform Set to Improve Patient Engagement
- The availability of NextGen's (NXGN) Patient Experience Platform is likely to enable high-quality healthcare and drive patient engagement.
- 03/18/2020
|
NextGen's New Platform Set to Improve Patient Engagement
- The availability of NextGen's (NXGN) Patient Experience Platform is likely to enable high-quality healthcare and drive patient engagement.
- 03/18/2020
|
Baxter (BAX) Q4 Earnings Beat Estimates, Revenues In Line
- Baxter's (BAX) fourth-quarter earnings benefit from higher revenues, solid segmental performance and growth in APAC.
- 03/17/2020
|
Baxter (BAX) Q4 Earnings Beat Estimates, Revenues In Line
- Baxter's (BAX) fourth-quarter earnings benefit from higher revenues, solid segmental performance and growth in APAC.
- 03/17/2020
|
HealthEquity (HQY) Q4 Earnings and Revenues Top Estimates
|
Here's Why You Should Hold Onto Varian Medical Stock Now
- Varian Medical (VAR) gains from solid prospects of its core Oncology Systems unit.
- 03/16/2020
|
Here's Why You Should Hold Onto Varian Medical Stock Now
|
Here's Why You Should Buy Cooper Companies (COO) Stock Now
- Cooper Companies (COO) lifts adjusted earnings per share view for fiscal 2020.
- 03/13/2020
|
Here's Why You Should Buy Cooper Companies (COO) Stock Now
- Cooper Companies (COO) lifts adjusted earnings per share view for fiscal 2020.
- 03/13/2020
|
Stocks That Hit 52-Week Lows On Thursday
|
Here's Why You Should Retain LHC Group (LHCG) Stock Now
- LHC Group (LHCG) continues to benefit from broad array of services and inorganic expansion. However, intense competition remains a woe.
- 03/12/2020
|
Here's Why You Should Hold on to CONMED (CNMD) Stock Now
- CONMED (CNMD) continues to benefit from robust international sales, broad product portfolio and persistent focus on R&D. However, forex remains a woe.
- 03/12/2020
|
Here's Why You Should Hold on to CONMED (CNMD) Stock Now
- CONMED (CNMD) continues to benefit from robust international sales, broad product portfolio and persistent focus on R&D. However, forex remains a woe.
- 03/12/2020
|
Here's Why You Should Retain LHC Group (LHCG) Stock Now
|
Stocks That Hit 52-Week Lows On Wednesday
- During Wednesday's morning session, 690 stocks hit new 52-week lows.
Intriguing Points:
Boeing (NYSE: BA) was the biggest company on a market cap basis to set a new...
- 03/11/2020
|
Here's Why You Should Retain HMS Holdings (HMSY) Stock Now
- HMS Holdings (HMSY) is gaining traction from growing PI and TPM analytical services.
- 03/11/2020
|
Here's Why You Should Retain HMS Holdings (HMSY) Stock Now
- HMS Holdings (HMSY) is gaining traction from growing PI and TPM analytical services.
- 03/11/2020
|
Global Medical Robots Industry
- Medical Robots market worldwide is projected to grow by US$15.8 Billion, driven by a compounded growth of 19.7%. Instruments & Accessories, one of the segments analyzed and sized in this study, displays the potential to grow at over 22.3%. The shifting dynamics supporting this growth makes it critical
- 03/09/2020
|
Is Accuray (ARAY) Outperforming Other Medical Stocks This Year?
- Is (ARAY) Outperforming Other Medical Stocks This Year?
- 03/06/2020
|
Is Accuray (ARAY) Outperforming Other Medical Stocks This Year?
- Is (ARAY) Outperforming Other Medical Stocks This Year?
- 03/06/2020
|
Cooper Companies (COO) Misses on Q1 Earnings, Lifts View
- Cooper Companies (COO) gains from core CVI segment in fiscal Q1.
- 03/06/2020
|
Cooper Companies (COO) Misses on Q1 Earnings, Lifts View
- Cooper Companies (COO) gains from core CVI segment in fiscal Q1.
- 03/06/2020
|
Here's Why You Should Invest in Intuitive Surgical Stock Now
- Intuitive Surgical (ISRG) continues to benefit from da Vinci surgical system, strong global foothold and solid recurring revenue base. However, stiff competition remains a woe.
- 03/06/2020
|
Is Accuray (ARAY) Outperforming Other Medical Stocks This Year?
|
Accuray Incorporated : Reports Inducement Awards Under NASDAQ Listing Rules | MarketScreener
- SUNNYVALE, Calif., March 5, 2020 /PRNewswire/ -- Accuray Incorporated today reported, as required by NASDAQ Stock Market Rules, equity inducement awards to Michael Hoge, the company's new… | March 5, 2020
- 03/05/2020
|
Accuray Incorporated Reports Inducement Awards Under NASDAQ Listing Rules
- Accuray Incorporated (NASDAQ: ARAY) today reported, as required by NASDAQ Stock Market Rules, equity inducement awards to Michael Hoge, the company's new Senior Vice President, Global Operations. As a material inducement to Mr. Hoge joining the company, and in accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of the company unanimously approved granting Mr. Hoge (i) an award of 126,475 restricted stock units covering shares of the company's common stock, and (ii) a stock option to purchase 277,305 shares of the company's common stock, in each case effective as of February 28 (collectively, the "Inducement Awards"). The Inducement Awards were made outside of the company's current equity plan, but are subject to terms and conditions generally consistent with those in the company's 2016 Equity Incentive Plan.
- 03/05/2020
|
Here's Why You Should Hold on to OPKO Health Stock for Now
- OPKO Health (OPK) continues to gain from RAYALDEE and BioReference platforms, and focus on R&D despite operating losses.
- 03/05/2020
|
Here's Why You Should Hold on to OPKO Health Stock for Now
|
Allscripts (MDRX) Q4 Earnings and Revenues Miss Estimates
- Allscripts (MDRX) fourth-quarter results gain from higher revenues along with growth in bookings. Contraction in both gross and operating margins remains a woe.
- 03/04/2020
|
Allscripts (MDRX) Q4 Earnings and Revenues Miss Estimates
- Allscripts (MDRX) fourth-quarter results gain from higher revenues along with growth in bookings. Contraction in both gross and operating margins remains a woe.
- 03/04/2020
|
Veeva Systems (VEEV) Q4 Earnings and Revenues Beat Estimates
- Veeva Systems (VEEV) gains from segmental strength in the fiscal fourth quarter.
- 03/04/2020
|
Veeva Systems (VEEV) Q4 Earnings and Revenues Beat Estimates
- Veeva Systems (VEEV) gains from segmental strength in the fiscal fourth quarter.
- 03/04/2020
|
Here's Why You Should Hold Avanos Medical (AVNS) Stock Now
- Avanos (AVNS) gains from solid fourth-quarter show despite headwinds in the Acute Pain business.
- 03/04/2020
|
Veeva Systems (VEEV) Q4 Earnings and Revenues Beat Estimates
|
What's in Store for Cooper Companies (COO) Q1 Earnings?
- Cooper Companies (COO) fiscal first-quarter performance is likely to reflect better-than-expected performance at CVI and CSI, and higher revenues.
- 03/03/2020
|
Here's Why You Should Invest in Integer Holdings Stock Now
- Integer Holdings (ITGR) continues to benefit from portfolio management, strong foothold in the broader MedTech space and rising Non-Medical sales.
- 03/03/2020
|
What's in Store for Cooper Companies (COO) Q1 Earnings?
|
Glaukos (GKOS) Q4 Earnings and Revenues Surpass Estimates
- Glaukos (GKOS) fourth-quarter results benefit from revenue growth. However, rise in operating expenses remains a concern.
- 03/02/2020
|
When Can We Expect A Profit From Accuray Incorporated (NASDAQ:ARAY)?
- Accuray Incorporated's (NASDAQ:ARAY): Accuray Incorporated designs, develops, and sells radiosurgery and radiation...
- 03/01/2020
|
Why Is Accuray (ARAY) Down 28.2% Since Last Earnings Report?
- Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- 02/27/2020
|
Why Is Accuray (ARAY) Down 28.2% Since Last Earnings Report?
- Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- 02/27/2020
|
LHC Group (LHCG) Q4 Earnings Meet Estimates, Revenues Lag
- LHC Group (LHCG) fourth-quarter results benefit from home health and hospice admissions and higher revenues.
- 02/27/2020
|
Avanos (AVNS) Earnings and Revenues Beat Estimates in Q4
|
Nevro (NVRO) Q4 Loss Narrower Than Expected, Revenues Up Y/Y
- Nevro (NVRO) sees strong segmental contributions in Q4.
- 02/26/2020
|
Nevro (NVRO) Q4 Loss Narrower Than Expected, Revenues Up Y/Y
- Nevro (NVRO) sees strong segmental contributions in Q4.
- 02/26/2020
|
Orthofix (OFIX) Q4 Earnings Match Estimates, Margins Decline
- We are upbeat about the year-over-year revenue growth recorded by majority of Orthofix's (OFIX) key operating segments in Q4.
- 02/26/2020
|
Inogen's (INGN) Q4 Earnings Miss, Revenues Top Estimates
- Inogen (INGN) sees segmental softness in the fourth quarter.
- 02/26/2020
|
Inogen's (INGN) Q4 Earnings Miss, Revenues Top Estimates
- Inogen (INGN) sees segmental softness in the fourth quarter.
- 02/26/2020
|
Orthofix (OFIX) Q4 Earnings Match Estimates, Margins Decline
|
First Accuray CyberKnife® M6™ System Installed in Missouri at Mercy Hospital St. Louis
- SUNNYVALE, Calif., Feb. 25, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Mercy Hospital St. Louis continues to demonstrate its commitment to improving patient outcomes with the installation of the first CyberKnife® M6™ System in Missouri at their…
- 02/25/2020
|
Merit Medical (MMSI) Q4 Earnings & Revenues Beat Estimates
|
HMS Holdings (HMSY) Q4 Earnings and Revenues Miss Estimates
|
Integer Holdings (ITGR) Q4 Earnings & Revenues Top Estimates
- Integer Holdings' (ITGR) fourth-quarter earnings benefit from higher revenues and strong segmental performance.
- 02/21/2020
|
Fresenius Medical (FMS) Q4 Earnings Beat Estimates, Up Y/Y
|
Has Accuray (ARAY) Outpaced Other Medical Stocks This Year?
- Is (ARAY) Outperforming Other Medical Stocks This Year?
- 02/19/2020
|
The Zacks Analyst Blog Highlights: Smith Micro Software, Accuray, Vista Outdoor, Synaptics and CareDx
- The Zacks Analyst Blog Highlights: Smith Micro Software, Accuray, Vista Outdoor, Synaptics and CareDx
- 02/19/2020
|
The Zacks Analyst Blog Highlights: Smith Micro Software, Accuray, Vista Outdoor, Synaptics and CareDx
- The Zacks Analyst Blog Highlights: Smith Micro Software, Accuray, Vista Outdoor, Synaptics and CareDx
- 02/19/2020
|
Amedisys (AMED) Q4 Earnings Beat Estimates, Revenues Miss
|
Trump Mulling Tax Cuts to Incentivize Stock Buying? 6 Picks
- President Trump's tenure has seen Wall Street perform exceptionally well so far. In fact, Trump often cites Wall Street's bull run as a reflection of his good governance.
- 02/18/2020
|
